News of further investment in GDNF, or Glial Cell-Line Derived Neurotrophic Factor, has been released by Parkinson’s UK today. GDNF is a nerve growth protein that supports neurons and encourages their growth and survival during development. This is important news for the whole Parkinson’s community and a step that is welcomed by the Cure Parkinson’s team.
GDNF is a drug that’s been championed and invested in by Cure Parkinson’s and its late co-founder, Tom Isaacs, since 2003. We are delighted that money is being committed to determine if there is merit in a further trial and how the challenges of previous trials can be overcome. This is an exciting day for the Parkinson’s community
Will Cook, CEO – Cure Parkinson’s
